Health Condition 1: J309- Allergic rhinitis, unspecified
Conditions
Interventions
Intervention1: Allium Sativum group: Homoeopathic medicine Allium sativum in 200C potency procured from a licensed homoeopathic pharmacy having GMP certification administered orally in medicated globu
Sponsors
Central Council for Research in Homoeopathy
Eligibility
Inclusion criteria
Inclusion criteria: 1. Participants presenting with or having a history of two or more nasal symptoms (watery discharge, nasal obstruction, sneezing and nasal itching) for more than 4 days a week and for more than 4 consecutive weeks as per ARIA Classification 2. Participants having a cutoff value of greater than or equals to 7 for Score for Allergic Rhinitis (SFAR) during screening. 3. Participants with positive skin prick test to any one or more allergens. 4. Participants with elevated levels of Serum IgE. 5. Participants who are not taking any homoeopathic medication for their acute presenting complaints. 6. Participants who are already on treatment with antihistamines or any other anti-allergic medication but agreeing on a washout period of 7 days. 7. Participants willing to participate in the study and giving written informed consent
Exclusion criteria
Exclusion criteria: 1. Participants with severe deviated nasal septum, nasal polyp, nasal growths, adenoids, asthma, sinusitis. 2. Participants with a known history of uncontrolled or life-threatening disease/ systemic illness (tuberculosis, cancer, AIDS, diabetes, hypertension, cardiovascular disorders, etc.). 3. Any pre-existing psychiatric disorder. 4. Participants taking concomitant medications like immuno-suppressants, corticosteroids or other Ayush therapies/ herbal medicines, etc. for chronic ailments. 5. Substance abuse and/or dependence. 6. Pregnant and lactating women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.To compare the changes in TNSS profile scores 2.To compare the changes in the Serum IgE of the participants 3.Evaluate the change in gene expression markers related to allergic rhinitisTimepoint: At baseline and every 15 days till 3 months. At baseline, Day 45 & at the end of 3rd month. At baseline and at the end of 3rd month. | — |
Secondary
| Measure | Time frame |
|---|---|
| To measure the improvement in the overall impact on daily life by comparing the RQLQ scores. Timepoint: At baseline, and every 15 days till 3 months. ;To compare the changes in the AEC levels of the participants.Timepoint: At baseline, Day 45 & at the end of 3rd month. | — |
Countries
India
Contacts
Public ContactDr Sreekanth Gopinathan Pillai
Central Council for Research in Homoeopathy
Outcome results
None listed